Tempus AI Stock Surges 14% on FDA Clearance for Cardiac Imaging Platform

Tempus AI shares jumped nearly 14% Thursday after the FDA cleared an upgraded version of its AI-powered Tempus Pixel cardiac imaging platform. The healthcare technology company's rally far outpaced the broader market's 0.9% gain.

The regulatory milestone validates Tempus AI's approach to medical imaging technology. "This underscores our commitment to advancing AI-driven imaging that's both scientifically rigorous and clinically meaningful," said Chris Scotto Divetta, the company's SVP of AI applications.

Cardiac imaging represents a substantial addressable market within healthcare. The FDA clearance positions Tempus AI to capitalize on growing demand for AI-enhanced diagnostic tools. While cardiac health remains a focus, the company continues expanding its product portfolio across multiple medical specialties.